{"id":"n-13-ammonia-intravenous-injection","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201189","moleculeType":"Small molecule","molecularWeight":"16.03"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"N-13 ammonia is taken up by myocardial cells via the glutamate-glutamine cycle and becomes trapped intracellularly, with uptake correlating to regional myocardial blood flow. The positron emissions are detected by PET imaging to create maps of myocardial perfusion, allowing assessment of coronary artery disease, viability, and ischemia. This enables non-invasive evaluation of cardiac function and blood flow distribution.","oneSentence":"N-13 ammonia is a positron-emitting radiopharmaceutical that accumulates in viable myocardium proportional to regional blood flow, enabling visualization of cardiac perfusion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:19.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myocardial perfusion imaging for assessment of coronary artery disease"},{"name":"Evaluation of myocardial viability"},{"name":"Assessment of regional myocardial blood flow"}]},"trialDetails":[{"nctId":"NCT03275584","phase":"PHASE4","title":"Safety of PET MPI Using the CRCHUM N-13 Ammonia","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2018-01-30","conditions":"N-13 Ammonia Safety","enrollment":20000},{"nctId":"NCT05583721","phase":"PHASE2","title":"Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-10-10","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT04343209","phase":"","title":"Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)","status":"COMPLETED","sponsor":"Ionetix Corporation","startDate":"2020-09-14","conditions":"Myocardial Ischemia, Coronary Disease, Coronary Artery Disease","enrollment":170},{"nctId":"NCT03170817","phase":"","title":"Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-03-29","conditions":"Coronary Artery Disease","enrollment":15},{"nctId":"NCT01433705","phase":"PHASE1","title":"Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2011-11","conditions":"Heart Disease","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"N-13 ammonia intravenous injection","genericName":"N-13 ammonia intravenous injection","companyName":"Centre hospitalier de l'Université de Montréal (CHUM)","companyId":"centre-hospitalier-de-l-universit-de-montr-al-chum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"N-13 ammonia is a positron-emitting radiopharmaceutical that accumulates in viable myocardium proportional to regional blood flow, enabling visualization of cardiac perfusion. Used for Myocardial perfusion imaging for detection of coronary artery disease, Assessment of myocardial viability in patients with coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}